The in vitro activity of terbina ne alone and in combination with other antifungal agents was tested against isolates of Aspergillus fumigatus, A. avus and A. niger. Testing was performed in a modi ed National Committee for Clinical Laboratory Standards (NCCLS) macrodilution broth assay, and interactions were examined using a checkerboard design. Terbina ne was highly active against Aspergillus isolates (minimum inhibitory concentration [MIC] 0¢01 to 2 m g ml ¡1 ) with a primary fungicidal action (minimum fungicidal concentration [MFC] 0¢02 to 4 m g ml ¡1 ).
Introduction
Invasive aspergillosis is the most common invasive fungal infection worldwide due to a mould and is now a major cause of death in immunocompromised patients, particularly those undergoing bone marrow or organ transplantation [1] . More than 90% of invasive aspergillosis cases are caused by Aspergillus fumigatus, which is also the prime agent of allergic bronchopulmonary aspergillosis and other chronic forms of disease [2] . The clinical standard for treatment of aspergillosis is still amphotericin B, which exerts a potent cidal action but also causes serious side-effects, although newer formulations of this drug appear to have improved tolerability. Recently, itraconazole has found increasing use in aspergillosis, often subsequent to amphotericin B treatment. Nevertheless, these drugs are not always effective or tolerated in severely ill patients, and mortality remains high. There is therefore a high medical need for new therapies.
Terbina ne has good activity in vitro against A. fumigatus as well as other aspergilli and moulds [3] , and has been reported to have clinical ef cacy in isolated cases of aspergillosis [4] . Because of the life-threatening nature of these infections, an investigational drug such as terbina ne needs to be clinically tested in combination with the standard treatment. We have therefore investigated the antifungal interaction between terbina ne, amphotericin B and the triazoles itraconazole, uconazole and voriconazole against A. fumigatus isolates. Some of these isolates were obtained from patients who had been treated successfully with oral terbina ne, including in one case combined therapy with amphoter-icin B. In addition, isolates of A. avus and A. niger were also tested, since these species are occasionally pathogenic.
Methods

Fungal cultures
The clinical isolates studied were A. fumigatus NFI 0159 (Novartis collection), NFI 0239 (obtained from Prof. H. Yamaguchi, Teikyo University, Tokyo, Japan), NFI 4001 and NFI 4002 (both obtained from Dr M. Cambon, Clermont-Ferrand University Hospital, France), A.
avus NFI 4003 and NFI 4004 (Dr M. Cambon, Clermont-Ferrand University Hospital, Clermont-Ferrard, France), and A. niger NFI 0921 (Novartis collection). The test strains were selected on the basis of known virulence and to include the major pathogenic Aspergillus species. Isolates NFI 4001 to NFI 4004 were from leukemia patients with invasive aspergillosis successfully treated with high-dose terbina ne in combination with other agents, while NFI 0159 and NFI 0239 have been employed in animal models.
Antifungal drugs
Terbina ne hydrochloride, itraconazole and voriconazole were synthesized at Novartis. Fluconazole was puri ed from commercial tablets of Di ucan (P zer/ Roerig, Latina, Italy) and amphotericin B, formulated as Fungizone, was purchased from Bristol-Myers Squibb GmbH (Munich, Germany). Drug potency was routinely monitored by assaying against standard quality control strains of Candida [5] .
Antifungal testing
Minimum inhibitory concentrations (MIC) were determined in broth macrodilution assays according to a modi cation of the National Committee for Clinical Laboratory Standards (NCCLS) M27-A protocol [5] , as detailed in a previous report [6] . Inocula consisting of conidia and hyphal fragments were prepared from stocks frozen at ¡80 o C by dilution in growth medium to give a nal viable cell count of 2¢5 to 3 £ 10 3 cfu ml
¡1
. Each assay was performed with a duplicate series of drug dilutions in RPMI 1640 medium without NaHCO 3 but with L-glutamine (Gibco BRL, Paisley, UK) buffered at pH 7¢0 with 0¢165 M MOPS (Sigma M-8899) according to NCCLS guidelines [5] . Tubes were incubated 72 h at 35 o C in air. The MIC was de ned as the lowest drug concentration causing 100% inhibition of visible fungal growth. In the case of uconazole, endpoints corresponding to at least 80% inhibition of growth were also recorded.
For determination of the minimum fungicidal concentration (MFC), samples (0¢1 ml) were removed from the assay tubes at the end of the incubation. Cell viability was then checked by streaking onto Sabouraud 2% glucose agar plates which were incubated at 35 o C for 72 h. The MFC was de ned as the lowest drug concentration at which no fungal colonies developed.
Analysis of interactions
Combination studies were performed in a checkerboard design using the assay described above to provide a matrix of all possible dose combinations of the two drugs within the required concentration range. The nature of the interaction between the two drugs was de ned quantitatively by means of the fractional inhibitory concentration index (FICI) [7] , which was calculated by the following formula:
Interpretation of the FICI was as follows: µ 0¢5, synergy; > 0¢5 but µ 1, additive; > 1 but µ 2, indifferent; > 2, antagonism. In practice, synergy calculated in this way is equivalent to a reduction of at least two dilution steps in the MIC of each drug when they are combined.
Results
Susceptibilities of Aspergillus isolates
Terbina ne displayed primary fungicidal activity against all isolates (Table 1) , the non-A. fumigatus Aspergillus species being much more susceptible than A. fumigatus, in agreement with earlier data. Amphotericin B was uniformly fungicidal against all of the Aspergillus isolates, as expected. Itraconazole gave the lowest MIC values of the drugs tested, but was not fungicidal against A. fumigatus and A. niger. Voriconazole also showed good in vitro activity and a primary cidal action against most of the isolates, con rming previous reports [8] . In contrast, uconazole was not active in this assay, even when MIC was de ned with an end-point of approximately 80% inhibition of fungal growth.
Combination of terbina ne and amphotericin B
Drug combinations were tested in the four isolates of A. fumigatus and one isolate of A. niger, and the results of the checkerboard assays are summarized in Table 2 . The interaction between terbina ne and amphotericin B was classi ed as additive in one strain of A. fumigatus and synergistic in the other four strains tested. In the isolates showing synergistic interaction, the presence of a low concentration of amphotericin B resulted in a two-step reduction in the MIC for terbina ne. However, the reverse effect did not occur; low concentrations of terbina ne did not decrease the MIC for amphotericin B. In view of this asymmetry, the term 'additive' is probably the best description for the interaction.
Interaction of terbina ne and triazoles
The combination of terbina ne and itraconazole exhibited an exceptionally powerful synergy against all ve Aspergillus strains, as evidenced by the very low values of the calculated FICI (Table 2) . Synergy was also displayed in terms of fungicidal activity (Table 3 ) and viable organisms were eliminated at combined drug concentrations which were well within the therapeutically attainable range. Similarly, combinations of terbina ne and voriconazole displayed potent synergy against all ve isolates, with very low MICs. Only slightly higher drug concentrations were needed for a fungicidal action, re ecting the cidal nature of the two individual drugs (Table 3) .
Although uconazole alone was devoid of activity against the Aspergillus isolates even with an endpoint of partial (80%) growth inhibition, low concentrations of uconazole caused a reduction of the MIC for terbina- ne. The interaction was additive to synergistic, using an endpoint of 100% growth inhibition. Low concentrations of terbina ne did not improve the activity of uconazole. Interestingly, low concentrations of uconazole also potentiated the cidal activity of terbina ne (Table 3) .
Discussion
The MICs of terbina ne against Aspergillus strains using the modi ed NCCLS assay are similar to those previously reported using other broth macrodilution assays [3, [9] [10] [11] . The exact nature of the test conditions thus does not appear to be a critical variable in susceptibility testing of this organism with terbina ne. To date, Aspergillus strains with appreciably higher MIC values have not been reported. The present results also con rm the previously noted primary fungicidal action of terbina ne against these species.
Amphotericin B, like other polyenes, is thought to act by complexing with ergosterol in the fungal cell membrane. This would suggest that ergosterol biosynthesis inhibitors such as allylamines or azoles might be antagonistic to the action of amphotericin B, but there are little experimental data to clarify this problem. In Cryptococcus, antagonism was observed between terbina ne and amphotericin B in vitro, but was not described in detail [12] . A similar effect has been reported for uconazole with amphotericin B in C. albicans [13] , and indeed itraconazole-induced resistance to amphotericin B has been reported at the clinical level [14] . Nevertheless, amphotericin B is often used clinically in combination with triazoles [15] , and there is an earlier report of successful treatment of a case of zygomycosis using combined oral terbina ne and amphotericin B [16] . A rare case of cutaneous aspergillosis caused by Aspergillus ustus was successfully treated with amphotericin B combined with topical terbina ne [17] . The current nding of a positive interaction between terbina ne and amphotericin B in vitro thus supports the clinical application of this combination. The lack of antagonism between the two drugs is most important for clinical testing, and was recently con rmed in vivo in a rabbit model of invasive aspergillosis [18] . In vitro synergy (FICI < 0¢5) was only observed at combinations of low amphotericin B and high (near-MIC) terbina ne concentrations, suggesting that the two drugs are not truly synergistic on a mechanistic level. One interpretation would be that amphotericin B facilitates the cellular uptake of terbina ne.
The potent synergy and fungicidal action of terbinane combined with itraconazole is compatible with the high activity of both drugs against Aspergillus species. Synergy between terbina ne and azoles has been reported in a number of other fungi such as Candida species [19] [20] [21] [22] and is presumed to be due to the combined effects of the drugs on different stages of the ergosterol biosynthesis pathway [19] . There are also case reports of successful clinical application of combined terbina ne and itraconazole in mycetoma [23] and Scopulariopsis infection [24] . Synergy of terbina ne with the recently developed drug voriconazole is also of potential therapeutic interest, and has not previously been reported.
Fluconazole appears to be almost completely inactive against Aspergillus in vitro, and clinically is reported to be poorly effective against mould infections even at high doses [25] . The observation of a positive interaction between terbina ne and low concentrations of uconazole was therefore quite surprising and may be of clinical relevance in view of the fungicidal action which was demonstrated. As with amphotericin B, it may be speculated that low concentrations of uconazole facilitate cellular uptake of terbina ne, perhaps by interacting with multidrug transporter ef ux pumps which have recently been identi ed in Aspergillus [26] .
There are already a number of reports of clinical ef cacy of terbina ne in chronic aspergillosis [4, 27, 28] , including both immunocompetent and immunocompromised patients. Several patients with acute infections have also been treated [29] , including combination therapy with amphotericin B. All the strains tested in the present study showed a positive interaction with 
